ViroGates AS (FRA:EP2) Dividends Received


FRA:EP2 ViroGates AS FRA:EP2
44 GF Score
Price €1.45
GF Value €0.90
! 2 Warning Signs
View Full Analysis

What is ViroGates AS Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:EP2
44GF Score
ViroGates AS FRA:EP2
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is ViroGates AS (FRA:EP2) Overvalued in 2026?

Based on GuruFocus' analysis, ViroGates AS stock appears to be overvalued. The current stock price of €1.45 is trading 61.1% above its estimated GF Value™ of €0.90.

Key valuation signals for FRA:EP2:

  • Dividends Received:
  • GF Value™: €0.90 vs. price of €1.45 (61.1% above fair value)
  • GF Score™: 44/100 with 2 warning signs

No single metric tells the full story. See the FRA:EP2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ViroGates AS Business Description

Other Exchanges VIRO:Denmark
Address Banevaenget 13, Birkerod, DNK, 3460
ViroGates AS is an international medical technology company that develops and markets blood tests to measure chronic inflammation at health clinics and hospitals. The company markets its blood test products under the suPARnostic brand. Its product portfolio comprises suPARnostic TurbiLatex, suPARnostic Quick Triage, and suPARnostic Auto Flex ELISA kit. These products are mainly used to measure the suPAR (soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream.
44GF Score

Get the complete analysis for FRA:EP2

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.45
Price
€0.90
GF Value